GlassScriptPhysician profile
Daniel A Rozas
NPI 1649432006
$9,566.44
in general payments reported to CMS, 2019-2025
41 companies · $2,937 in 2025
The $2,937 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $469 · 2021: $751 · 2022: $1,195 · 2023: $1,631 · 2024: $2,163 · 2025: $2,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,600 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,600.42 |
| Education | $130.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,022.11 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,734.14 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Insmed, INC. | $861.13 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $612.37 | 2022-2025 | Tezspire, Tavneos |
| Genzyme Corporation | $546.77 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.05 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $349.14 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $334.24 | 2020-2025 | Dupixent |
| Electromed, INC. | $304.41 | 2021-2025 | Smartvest |
| United Therapeutics Corporation | $230.58 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Actelion Pharmaceuticals US, INC. | $165.14 | 2020-2024 | Opsumit, Uptravi |
| Grifols USA, LLC | $157.50 | 2022-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $149.47 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $139.52 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $136.91 | 2023-2025 | Inspire |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $111.80 | 2019-2024 | (Ae4) Secretion Management |
| Inogen, INC. | $107.76 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Merck Sharp & Dohme LLC | $97.22 | 2023-2025 | Keytruda, Winrevair |
| Teva Pharmaceuticals USA, INC. | $96.50 | 2020-2022 | |
| Beigene USA, INC. | $91.76 | 2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $80.89 | 2019-2025 | |
| Lilly USA, LLC | $79.72 | 2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $73.37 | 2020-2025 | |
| 3b Medical, INC. | $56.11 | 2023-2024 | Luna |
| Bayer Healthcare Pharmaceuticals INC. | $54.46 | 2022-2023 | |
| Abbvie INC. | $53.70 | 2022-2025 | |
| Pulmonx Corporation | $51.34 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Shionogi INC | $48.90 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $47.85 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $39.40 | 2021-2022 | |
| Resmed Corp | $37.31 | 2023-2024 | |
| Itamar Medical INC | $24.50 | 2025 | Watchpatone |
| Vifor Pharma, INC. | $24.48 | 2024 | Zemaira |
| Sunovion Pharmaceuticals INC. | $23.65 | 2019 | |
| Viatris Specialty LLC | $22.45 | 2025 | Yupelri |
| Biogen, INC. | $21.75 | 2021 | |
| Gilead Sciences, INC. | $20.47 | 2021 | |
| Vapotherm INC | $19.74 | 2022 | |
| Nabriva Therapeutics, Plc | $17.22 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rozas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.